Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

Trial StartCasdatifanPD-L1/VEGF-A Bispecific ImmunomodulatorPositive

AI Analysis

Summary

Arcus Biosciences announced a clinical trial collaboration and supply agreement to evaluate Casdatifan in combination with a PD-L1/VEGF-A bispecific immunomodulator for treating kidney cancer.

Clinical Trial Data

Importance:5/10

Sentiment:

0.30

clinical_trialcollaborationcombination_therapyoncologyimmunotherapy

Related Companies

$RCUS

Read the original article

Published by yahoo_finance on June 3, 2026 12:00 PM

Read Original